Press Releases

The latest press releases from bridge therapeutics

04/23/19 Bridge Therapeutics Announces the Addition of Edward J. Minskoff to Its Board of Directors

Bridge Therapeutics is pleased to announce the addition of Edward J. Minskoff to its board of directors. 

April 23, 2019 

As a major Manhattan real estate acquirer and developer of 40 million square feet of commercial space, Edward J. Minskoff brings decades of financial and business experience to Bridge. On joining Bridge’s board, Mr. Minskoff commented, “I see Bridge improving the healthcare of millions as it becomes a highly successful pharmaceutical company.”

Read the full article here 

11/07/18 Dr. Steven Passik Has Joined the Scientific Advisory Board of Bridge Therapeutics

Steve Passik PhD, a recognized leader and researcher in pain management and addiction joins Bridge Therapeutics Scientific Advisory Board.

November 7, 2018

Dr. Passik has been a Principal Investigator for numerous clinical trials funded by both pharmaceutical companies and government funded organizations. The intersection of pain and addiction has been the focus for much of his teaching activities and peer reviewed articles. He has written extensively on the treatment of cancer and AIDS patient’s pain management.

Read full article here

11/02/18 Bridge Therapeutics Announces the Addition of Dr. Bob Rappaport to Its Scientific Advisory Board

As their newest member, Dr. Bob Rappaport brings decades of drug approval experience to Bridge Therapeutics’ Scientific Advisory Board. 

November 2, 2018 

Dr. Rappaport spent 20 years at the Food and Drug Administration, with the last 12 years as Director of the Anesthesia, Analgesia, and Addiction Products Division at the Center for Drug Evaluation and Research. There he oversaw the approvals of drug products for that sector. Prior to his retirement, Dr. Rappaport received the FDA Lifetime Achievement Award.

Read the full article here

10/31/18 Bridge Therapeutics is Selected as a Finalists for the RESI 2018 Innovation Challenge

Bridge Therapeutics will present a poster presentation at the RESI Conference November 4, 2018, in New York.

October 31, 2018

Bridge Therapeutics has been selected by Life Science Nation’s internal scientific review board to be part of the Innovation Challenge presenting its technology in an exhibition-style format throughout the full-day RESI Conference on November 4, 2018, in New York. Being a Finalist gains Bridge additional exposure to investors and potential partners by showcasing its company and products through a dedicated poster in the Exhibit Hall.

Read the full article here


09/21/18 Dr. Bob Raffa Joins Bridge Therapeutics’ Scientific Advisory Board Bringing Decades of Research and Experience

Pharmaceutical startup Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific Advisory Board member. 

September 21, 2018 

Dr. Raffa is a global leader in pharmacology, with over 40 years of preclinical research on drug abuse and analgesic drug discovery. He has held many prestigious leadership roles, including Co-Leader for analgesic drug discovery at Johnson & Johnson where he attained the level of Research Fellow, as well as being Professor Emeritus at Temple University School of Pharmacy.

Read the full article here

09/04/18 Bridge Therapeutics Team to Speak on Tackling a Key Source of the Opioid Crisis

Dr. Greg Sullivan, Chief Scientific Officer, Dr. Dave Bergstrom. Chief Operations Officer, and Tim Peara of will be speaking about how Bridge Therapeutics’ lead investigational drug could be a key part of ending the opioid crisis.

September 4, 2018

Each year 70 million Americans will take an opioid for pain. Of these, 17 million take a strong opioid daily. It is these 17 million patients who are most at risk of addiction disorders leasing to shattered relationships, overdoes, and possibly death. 70% of opioid overdose victims started by abusing pain medication. A key part to ending the Opioid Crisis will be providing a safer therapy than opioids for chronic pain.

Read the full article here

07/19/18 Bridge Therapeutics, to Participate in American Chronic Pain Association Roundtable With Agenda for Chronic Pain Drug Development Program

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they will be introducing their chronic pain development program at the American Chronic Pain Association (ACPA) Roundtable. The ACPA offers peer support and education in pain management skills to people with chronic pain, along with their families, friends, and healthcare professionals.

July 11, 2018

Alton Kelley, Director of Business Development for Bridge Therapeutics, said this roundtable will give the chronic pain community an opportunity to learn more about Bridge Therapeutics’ current developments on pain relievers and promoting the ACPA’s efforts in fighting chronic pain.

Read the full article here

07/10/18 Pharma Startup, Bridge Therapeutics, Will Unveil Its Chronic Pain Drug Development Program at the 2018 Young Startup Ventures Summit in New York

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they would showcase their chronic pain drug development program to venture capitalists at the 2018 Young Startup Ventures Summit in New York.

July 9, 2018

More than 150 venture capitalists will hear pitches and programs from various companies and startups in fields ranging from fintech to life sciences. The 2018 New York Venture Summit will take place at Convene in New York on July 10-11. Tim Peara said this forum would enable venture capitalist to hear how Bridge’s work towards developing a safer alternative for chronic pain has been progressing.

Read More

05/16/18 Pharmaceutical Startup, Bridge Therapeutics, Announces New Headquarters in Birmingham, Alabama

Bridge Therapeutics has announced they will be expanding their operations into one of the finest locations in Birmingham, Alabama. The new headquarters at the Summit in Birmingham is currently under design by the award-winning architectural firm Chambless King Architects.

May 16, 2018

“Our new headquarters will bring a new energy to Bridge Therapeutics,” said Alton Kelley, Director of Business Development. “We are all excited about this next step. We hope our new headquarters will attract other businesses to the Birmingham area, and ignite new economic growth in our community.”

John Chambless, the lead architect behind the new office design, said he wanted the new space to convey a sense of growth and change to investors and partners who visit there.

Read the full article here


03/14/18 Pharmaceutical Startup, Bridge Therapeutics, Announces Tim Peara Will Be Joining the Company as the Director of Finance

The innovative late development-stage pharmaceutical startup, Bridge Therapeutics has announced Tim Peara will be joining its management team as the new Director of Finance, effective immediately.

March 14, 2018

Tim Peara has more than 30 years of experience with institutional investments and technology start-ups. He has negotiated and structured investments, conducted due diligence, and built financial models for companies in finance, energy tech, and industry. Mr. Peara has also built and led teams while consulting to a variety of businesses.

Tim holds a BA in Latin American Studies from Wesleyan University in Connecticut and an MBA in Finance & International Business from the University of Chicago’s Booth School of Business.

Read More


For more information about Bridge Therapeutics please contact us today using the form below.